We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arthur J. Gallagher Buys Doyle Group, Boosts Affinity Business
Read MoreHide Full Article
Arthur J. Gallagher & Co. (AJG - Free Report) recently acquired The Doyle Group, Inc. and its affiliates, collectively doing business as Direct To PolicyHolder. The terms of the transaction have not been revealed.
Florida-based Direct To PolicyHolder was founded in 2010. The company is an e-commerce affinity platform operating via proprietary digital marketing protocols, attribution modeling and affinity channel marketing. It caters to acquisition, conversion and retention of professional liability (E&O) insurance policyholders in the allied healthcare and wellness fields. Thus, the addition to Arthur J. Gallagher’s portfolio will help enhance its Gallagher Affinity operations.
Arthur J. Gallagher is one of the top five global brokers, having a presence in the United States, Australia, Bermuda, Canada, the Caribbean, New Zealand and the United Kingdom. This marks the fourth buyout in the ongoing quarter. The company had made 17 buyouts in the year-ago quarter with estimated annualized revenues of $84.3 million. Its merger and acquisition pipeline is quite strong with about $400 million of revenues, which is expected to fuel inorganic growth. Given its solid capital position, the company is well poised to pursue more strategic buyouts. The company targets about $1.5 billion of mergers and acquisitions with free cash and debt.
This Zacks Rank #3 (Hold) insurance broker remains focused on its long-term growth strategies of delivering organic revenue growth and pursuing strategic mergers and acquisition. It is also focused on productivity improvements and quality enhancements that should help it post sturdy numbers in the future.
Shares of Arthur J. Gallagher have gained 19.4% year to date, underperforming the industry’s rise of 25.2%. Nonetheless, the company’s efforts to ramp up its growth profile and capital position should continue to drive share price higher.
There have been a host of acquisitions in the insurance space of late, given the significant capital available. Recently, Brown & Brown’s (BRO - Free Report) unit Brown & Brown of Massachusetts, LLC acquired Poole Professional Companies. The acquisition will strengthen the acquirer’s products and services portfolio and enhance growth opportunities by catering to risk management issues faced by design professionals.
Stocks to Consider
A few better-ranked insurance brokers are eHealth (EHTH - Free Report) and Willis Towers Watson Public Limited Company .
eHealth operates through two segments and provides services like private health insurance exchange in the United States and China to families, individuals and small businesses. The company came up with average four-quarter positive surprise of 167.16%. The company sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Willis Towers Watson Public Limited Company operates as an advisory, broking, and solutions company worldwide. It offers actuarial support, plan design, and administrative services for traditional pension and retirement savings plans. The company came up with average four-quarter positive surprise of 4.56%. The company carries a Zacks Rank #2 (Buy).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Arthur J. Gallagher Buys Doyle Group, Boosts Affinity Business
Arthur J. Gallagher & Co. (AJG - Free Report) recently acquired The Doyle Group, Inc. and its affiliates, collectively doing business as Direct To PolicyHolder. The terms of the transaction have not been revealed.
Florida-based Direct To PolicyHolder was founded in 2010. The company is an e-commerce affinity platform operating via proprietary digital marketing protocols, attribution modeling and affinity channel marketing. It caters to acquisition, conversion and retention of professional liability (E&O) insurance policyholders in the allied healthcare and wellness fields. Thus, the addition to Arthur J. Gallagher’s portfolio will help enhance its Gallagher Affinity operations.
Arthur J. Gallagher is one of the top five global brokers, having a presence in the United States, Australia, Bermuda, Canada, the Caribbean, New Zealand and the United Kingdom. This marks the fourth buyout in the ongoing quarter. The company had made 17 buyouts in the year-ago quarter with estimated annualized revenues of $84.3 million. Its merger and acquisition pipeline is quite strong with about $400 million of revenues, which is expected to fuel inorganic growth. Given its solid capital position, the company is well poised to pursue more strategic buyouts. The company targets about $1.5 billion of mergers and acquisitions with free cash and debt.
This Zacks Rank #3 (Hold) insurance broker remains focused on its long-term growth strategies of delivering organic revenue growth and pursuing strategic mergers and acquisition. It is also focused on productivity improvements and quality enhancements that should help it post sturdy numbers in the future.
Shares of Arthur J. Gallagher have gained 19.4% year to date, underperforming the industry’s rise of 25.2%. Nonetheless, the company’s efforts to ramp up its growth profile and capital position should continue to drive share price higher.
There have been a host of acquisitions in the insurance space of late, given the significant capital available. Recently, Brown & Brown’s (BRO - Free Report) unit Brown & Brown of Massachusetts, LLC acquired Poole Professional Companies. The acquisition will strengthen the acquirer’s products and services portfolio and enhance growth opportunities by catering to risk management issues faced by design professionals.
Stocks to Consider
A few better-ranked insurance brokers are eHealth (EHTH - Free Report) and Willis Towers Watson Public Limited Company .
eHealth operates through two segments and provides services like private health insurance exchange in the United States and China to families, individuals and small businesses. The company came up with average four-quarter positive surprise of 167.16%. The company sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Willis Towers Watson Public Limited Company operates as an advisory, broking, and solutions company worldwide. It offers actuarial support, plan design, and administrative services for traditional pension and retirement savings plans. The company came up with average four-quarter positive surprise of 4.56%. The company carries a Zacks Rank #2 (Buy).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>